Cynomolgus TNFSF11 / RANKL / CD254 Protein, His Tag, active trimer (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
RAL-C5243-50ug
$360.00
RAL-C5243-1mg (500ug X 2)
$2885.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    RANKL, CD254, TRANCE, OPGL, ODF

  • Source

    Cynomolgus TNFSF11 Protein, His Tag (RAL-C5243) is expressed from human 293 cells (HEK293). It contains AA Gly 136 - Asp 317 (Accession # A0A7N9DBU4).

    Predicted N-terminus: His

    Request for sequence
  • Molecular Characterization

    TNFSF11 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 22.4 kDa. The protein migrates as 30-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    TNFSF11 SDS-PAGE

    Cynomolgus TNFSF11 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    TNFSF11 SEC-MALS

    The purity of Cynomolgus TNFSF11 Protein, His Tag (Cat. No. RAL-C5243) is more than 85% and the molecular weight of this protein is around 75-85 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     TNFSF11 ELISA

    Immobilized Human RANK Protein, Mouse IgG2a Fc Tag (Cat. No. RAK-H5251) at 1 μg/mL (100 μL/well) can bind Cynomolgus TNFSF11 Protein, His Tag (Cat. No. RAL-C5243) with a linear range of 0.5-15 ng/mL (QC tested).

    Protocol
  •  TNFSF11 ELISA

    Immobilized Cynomolgus TNFSF11 Protein, His Tag (Cat. No. RAL-C5243) at 1 μg/mL (100 μL/well) can bind Human RANK Protein, Mouse IgG2a Fc Tag (Cat. No. RAK-H5251) with a linear range of 0.03-1 ng/mL (Routinely tested).

    Protocol
  •  TNFSF11 ELISA

    Immobilized Cynomolgus TNFSF11 Protein, His Tag (Cat. No. RAL-C5243) at 1 μg/mL (100 μL/well) can bind Anti-TNFSF11 Antibody, Human IgG1 with a linear range of 0.06-1 ng/mL (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.

Recent Advances

 
Drug Development Progress
  • English Name:

    Tumor necrosis factor ligand superfamily member 11

  • Category:

  • Approved Drugs:

    18 Details

  • Drugs in Clinical Trials:

    18 Details

  • Highest Development Stage:

    Approved

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland